Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | PLAT | P00750 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953284 | 0.81 | CCNB2 (0.43) | CCNB2CDK1CCNB1CCNB3GCGR | |
| SCHEMBL13778096 | 0.81 | ERCC1 (0.34) | MAPT | |
| SCHEMBL12953145 | 0.80 | ERCC1 (0.50) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL13516530 | 0.71 | PLAT (0.48) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL18439807 | 0.70 | CCNB2 (0.43) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL14545785 | 0.70 | KDM5A (0.40) | PLATMAPT | |
| SCHEMBL10313454 | 0.70 | ALDH1A1 (0.41) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL10313591 | 0.69 | KDM4E (0.41) | CYP19A1PLATMAPT | |
| SCHEMBL31468364 | 0.69 | KDM4E (0.41) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL31468421 | 0.69 | DRD1 (0.37) | GCGRMAPK14PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7807683-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-08 | — | — | US | disclosed |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | SCHERING CORPORATION | 2007-02-15 | — | — | US | disclosed |
| US-7161003-B1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | CCNB2 51/4885CDK1 3/4885CCNB1 48/4885 |
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CCNB2 50/4885CDK1 2/4885CCNB1 46/4885 |
| US-20070054925-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CCNB2 50/4885CDK1 2/4885CCNB1 46/4885 |
| US-20070037824-A1 | Enzyme inhibitors from pyrazolo[1,5a]pyrimidine as enzyme inhibitors | CDK2, CDK5, CDKN1A | CCNB2 63/4885CDK1 5/4885CCNB1 52/4885 |
| US-20070054906-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CCNB2 50/4885CDK1 2/4885CCNB1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.